Operates China's first large-scale DPF (Designated Pathogen-Free) facility for gene-edited pigs.
Utilizes barrier environments combined with caesarean section delivery to eliminate pathogens.
Breeds transplant donor pigs free of cross-species infection risks for clinical use.
| Main Genotype | Breeding Generation |
| GTKO | > F16 |
| GTKO/SdaKO/CMAHKO（TKO） | F5 |
| TKO/hCD55/hCD46/hTHBD（Clinical Research） | F2 |
Pigs exhibit higher level of genomic similarity to humans than mice.
Widely used for modeling human diseases, drug evaluation, and therapeutic development.
HumanBody Weight(KG)40-100 Heart Weight(G)200-300 Heart Rate(bpm)60-100 |
PigBody Weight(KG)40-120 Heart Weight(G)230-330 Heart Rate(bpm)60-100 |
MouseBody Weight(KG)0.03-0.05 Heart Weight(G)0.15-0.2 Heart Rate(bpm)470-780 |
| Disease Models | Technical Highlights |
| Atherosclerosis | Dual-gene modification model; genes involved in lipid metabolism regulation (contact for details) |
| Immunodeficiency | Dual-gene modification model affecting adaptive immune function (contact for details) |
| Skeletal Muscle Growth Regulation | Single-gene modification model regulating muscle development pathway (contact for details) |
| Hypolipidemia and Anti-Atherosclerosis | Single-gene modification model involving lipid metabolism and vascular protection mechanisms (contact for details) |
| Hereditary Tyrosinemia | Single-gene modification model affecting amino acid metabolism pathway (contact for details) |
Current clinical decellularized biomaterial products face the issue of α-Gal antigen residues. Genetic knockout can completely eliminate α-Gal antigens from porcine-derived materials, providing significant advantages for developing low-immunogenicity biomaterial products.
Operates a 133-mu (approx. 22 hectares) biomedical pig breeding and research Facility with over 9,000 m² of built-up facilities, meticulously designed into 9 functional zones.
Maintains a breeding herd of 2,000 pigs with an annual production capacity of 3,000 pigs.
Breeds premium donor pigs with well-defined genetic backgrounds and certified SPF (Specific Pathogen-Free) status, delivering high-quality experimental pigs for vaccine development, medical device and pharmaceutical evaluation, and driving innovation in the biomedical sector.
Technology Platforms:
| Type | Platform |
| Core R&D Platforms | Gene-Editing Platform |
| Core R&D Platforms | Somatic Cell Cloning Platform |
| Core R&D Platforms | Chimeric Research Platform |
| Resource & Quality System | Gene-Edited Donor Pig Breeding Platform |
| Resource & Quality System | Pathogen Monitoring Platform |
| Resource & Quality System | DPF Biosecurity Purification Platform |
| Translational & Validation Platforms | Immune Analysis Platform |
| Translational & Validation Platforms | Preclinical Trial Multi-Center Network |
| Translational & Validation Platforms | Early-Stage Translational Research Multi-Center Network |
State-of-the-art laboratory complex includes:
Specimen collection and necropsy room.
Class 1000 (ISO Class 6) animal operating room.
Class 10,000 (ISO Class 7) cell culture laboratory Equipped with advanced instrumentation: Ventilator anesthesia systems.
Multi-parameter physiological monitors (ECG/SpO₂/ETCO₂) Digital ultrasound diagnostic equipment.
Negative-pressure dissection stations.
Leveraging SPF-grade medical pigs and integrated biomedical platforms, we deliver fully customized R&D solutions to meet clients' specific requirements.
|
|
| No. | Product | Application |
| 1 | Gene-edited porcine kidney donors (contact for details) | End-stage renal disease (ESRD) |
| 2 | Gene-edited porcine liver donors (contact for details) | Acute liver failure |
| 3 | Gene-edited porcine red blood cells (contact for details) | Oxygen carriers for normothermic machine perfusion |
| 4 | Fresh gene-edited porcine skin grafts (contact for details) | Emergency treatment for major burns |
| 5 | Viable gene-edited porcine skin (contact for details) | Chronic deep wound dressing |
